title: Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
abstract: The activity of aminoglycosides, which are used to treat Pseudomonas aeruginosa respiratory infection in cystic fibrosis (CF) patients, is reduced under the anaerobic conditions that reflect the CF lung in vivo. In contrast, a 4:1 (wt/wt) combination of fosfomycin and tobramycin (F:T), which is under investigation for use in the treatment of CF lung infection, has increased activity against P. aeruginosa under anaerobic conditions. The aim of this study was to elucidate the mechanisms underlying the increased activity of F:T under anaerobic conditions. Microarray analysis was used to identify the transcriptional basis of increased F:T activity under anaerobic conditions, and key findings were confirmed by microbiological tests, including nitrate utilization assays, growth curves, and susceptibility testing. Notably, growth in subinhibitory concentrations of F:T, but not tobramycin or fosfomycin alone, significantly downregulated (P < 0.05) nitrate reductase genes narG and narH, which are essential for normal anaerobic growth of P. aeruginosa. Under anaerobic conditions, F:T significantly decreased (P < 0.001) nitrate utilization in P. aeruginosa strains PAO1, PA14, and PA14 lasR::Gm, a mutant known to exhibit increased nitrate utilization. A similar effect was observed with two clinical P. aeruginosa isolates. Growth curves indicate that nitrate reductase transposon mutants had reduced growth under anaerobic conditions, with these mutants also having increased susceptibility to F:T compared to the wild type under similar conditions. The results of this study suggest that downregulation of nitrate reductase genes resulting in reduced nitrate utilization is the mechanism underlying the increased activity of F:T under anaerobic conditions.
authors: CF and Airways Microbiology Research Group, Queen's University, Belfast, United Kingdom.
authors: Gerard
authors: G
authors: McCaughey
authors: Deirdre F
authors: DF
authors: Gilpin
authors: Thamarai
authors: T
authors: Schneiders
authors: Lucas R
authors: LR
authors: Hoffman
authors: Matt
authors: M
authors: McKevitt
authors: J Stuart
authors: JS
authors: Elborn
authors: Michael M
authors: MM
authors: Tunney
mesh_terms: D000693:Anaerobiosis; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D004338:Drug Combinations; D005578:Fosfomycin / Q000494:pharmacology*; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D050901:Nitrate Reductase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D009566:Nitrates / Q000378:metabolism; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D014031:Tobramycin / Q000494:pharmacology*; D014158:Transcription, Genetic
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004338:Drug Combinations; D007527:Isoenzymes; D009566:Nitrates; D005578:Fosfomycin; D050901:Nitrate Reductase; D014031:Tobramycin
references: Thorax. 2011 Jul;66(7):579-84
references: 21270069
references: J Clin Microbiol. 2005 Oct;43(10):5085-90
references: 16207967
references: Int J Antimicrob Agents. 2010 Apr;35(4):333-7
references: 20071153
references: J Bacteriol. 2004 Jul;186(14):4596-604
references: 15231792
references: J Cyst Fibros. 2012 May;11(3):173-9
references: 22146482
references: J Bacteriol. 2005 Jul;187(14):4890-9
references: 15995204
references: Cell. 2007 Sep 7;130(5):797-810
references: 17803904
references: J Bacteriol. 2005 Nov;187(22):7561-8
references: 16267280
references: Can J Microbiol. 2009 Oct;55(10):1133-44
references: 19935885
references: Proc Natl Acad Sci U S A. 2006 May 30;103(22):8487-92
references: 16687478
references: Mol Microbiol. 2007 Jul;65(1):153-65
references: 17581126
references: PLoS Pathog. 2010 Jan 08;6(1):e1000712
references: 20072604
references: Infect Immun. 2011 Oct;79(10):4218-26
references: 21825069
references: J Bacteriol. 2009 Nov;191(22):6968-74
references: 19734311
references: BMC Microbiol. 2010 Jun 01;10:159
references: 20515462
references: Antimicrob Agents Chemother. 2012 May;56(5):2767-9
references: 22371901
references: J Cyst Fibros. 2012 May;11(3):163-72
references: 22138067
references: Biotechnol Bioeng. 2006 Apr 20;93(6):1069-78
references: 16435399
references: Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):677-87
references: 16249934
references: J Bacteriol. 2008 Dec;190(23):7762-72
references: 18820017
references: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14339-44
references: 14617778
references: J Med Microbiol. 2009 Sep;58(Pt 9):1133-1148
references: 19528173
references: Antimicrob Agents Chemother. 2009 Apr;53(4):1395-402
references: 19223646
references: J Bacteriol. 1998 Apr;180(7):1741-9
references: 9537370
references: J Bacteriol. 2008 Apr;190(8):2739-58
references: 18203836
references: J Clin Invest. 2006 Feb;116(2):436-46
references: 16440061
references: J Bacteriol. 2003 Dec;185(24):7247-56
references: 14645286
references: J Bacteriol. 2007 Jun;189(12):4449-55
references: 17400735
references: Science. 2013 Feb 8;339(6120):708-11
references: 23393266
references: Antimicrob Agents Chemother. 2009 Nov;53(11):4809-15
references: 19704123
references: J Bacteriol. 2003 Apr;185(7):2080-95
references: 12644477
references: Microbiol Rev. 1987 Dec;51(4):439-57
references: 3325794
references: Mol Microbiol. 2007 Apr;64(2):512-33
references: 17493132
references: J Bacteriol. 1999 Nov;181(21):6573-84
references: 10542156
references: Infect Immun. 2006 Jul;74(7):4237-45
references: 16790798
references: Antimicrob Agents Chemother. 2012 Mar;56(3):1529-38
references: 22232284
references: Infect Immun. 2007 Nov;75(11):5313-24
references: 17724070
references: Am J Respir Crit Care Med. 2008 May 1;177(9):995-1001
references: 18263800
references: J Cyst Fibros. 2012 Jul;11(4):349-52
references: 22325689
references: J Cyst Fibros. 2009 Jan;8(1):66-70
references: 18974024
references: Antimicrob Agents Chemother. 2003 Sep;47(9):2850-8
references: 12936984
references: Diagn Microbiol Infect Dis. 2010 Feb;66(2):181-6
references: 19828274
references: FEMS Microbiol Lett. 1997 Nov 1;156(1):55-60
references: 9368361
references: Infect Immun. 2005 Jun;73(6):3764-72
references: 15908409
references: J Bacteriol. 2007 Jun;189(11):4310-4
references: 17400734